Table 1.
Demographics and baseline characteristics of 116 patients with Chlamydia psittaci pneumonia
| Variables | All patients (N = 116) | Non-severe group (N = 63) | Severe group (N = 53) | p values (< 0.050) | Survival group (N = 43) | Non-survival group (N = 10) | p values (< 0.050) |
|---|---|---|---|---|---|---|---|
| Age, years | 59.7 (12.5) | 56.7 (13.0) | 63.2 (11.1) | 0.005 | 64.4 (10.2) | 58.0 (13.7) | 0.100 |
| 18–49 | 24 (20.7%) | 20 (31.7%) | 4 (7.5%) | 0.001 | 4 (7.5%) | 2 (20.0%) | 0.098 |
| 50–64 | 45 (38.8%) | 22 (34.9%) | 23 (43.4%) | 0.351 | 18 (41.9%) | 5 (50.0%) | 0.640 |
| Above 65 | 47 (40.5%) | 21 (33.3%) | 26 (49.1%) | 0.086 | 23(53.5%) | 3 (30.0%) | 0.181 |
| Sex | 0.796 | 0.574 | |||||
| Male | 84 (72.4%) | 45 (71.4%) | 39 (73.6%) | 31(72.1%) | 8(80%) | ||
| Female | 32(27.6%) | 18(28.6%) | 14(26.4%) | 12(27.9%) | 2(20%) | ||
| Smoke history | 22 (19.0%) | 12 (19.0%) | 10 (18.9%) | 0.980 | 7 (16.3%) | 1 (10.0%) | 0.449 |
| Expose history | 18 (15.5%) | 9 (14.3%) | 9 (17.0%) | 0.690 | 2 (4.7%) | 2 (20.0%) | 0.682 |
| Onset seasons | 0.222 | 0.827 | |||||
| Spring | 14 (12.1%) | 11 (17.5%) | 3 (5.7%) | 3 (7.0%) | 1 (10.0%) | ||
| Summer | 18 (15.5%) | 10 (15.9%) | 8(15.1%) | 8 (18.6%) | 2 (20.0%) | ||
| Autumn | 45 (38.8%) | 23 (36.5%) | 17 (32.1%) | 17 (39.5%) | 4 (40.0%) | ||
| Winter | 39 (33.6%) | 19 (30.2%) | 25 (47.6%) | 25(58.1%) | 3 (30.0%) | ||
| Coexisting conditions | |||||||
| Any | 47 (40.5%) | 22 (34.9%) | 25 (47.2%) | 0.181 | 18 (41.9%) | 7 (70.0%) | 0.047 |
| Respiratory diseases | 3 (2.6%) | 1 (1.6%) | 2 (3.8%) | 0.460 | 0 (0%) | 2 (20.0%) | < 0.001 |
| Diabetes | 21 (18.1%) | 10 (15.9%) | 11 (20.8%) | 0.496 | 9 (20.9%) | 2 (20.0%) | 0.871 |
| Cardiovascular diseases | 10 (8.6%) | 3 (4.8%) | 7 (13.2%) | 0.106 | 7 (16.3%) | 0 (0%) | 0.310 |
| Cerebrovascular diseases | 8 (6.9%) | 4 (6.3%) | 4 (7.5%) | 0.800 | 3 (7.0%) | 1 (10.0%) | 0.685 |
| Hypertension | 22 (19.0%) | 8 (12.7%) | 14 (26.4%) | 0.060 | 12 (27.9%) | 2 (20.0%) | 0.930 |
| Tumor | 1 (0.9%) | 1 (1.6%) | 0 (0%) | 0.357 | 0 (0%) | 0 (0%) | 0.758 |
| Liver diseases | 5 (4.3%) | 2 (3.2%) | 3 (5.7%) | 0.511 | 2 (4.7%) | 1 (10.0%) | 0.354 |
| Kidney diseases | 3 (2.6%) | 2 (3.2%) | 1 (1.9%) | 0.663 | 1 (2.3%) | 0 (0%) | 0.590 |
| Digestive diseases | 9 (7.8%) | 5 (7.9%) | 4 (7.5%) | 0.938 | 3 (7.0%) | 1 (10.0%) | 0.782 |
| Surgery history | 15 (12.9%) | 10 (15.9%) | 5 (9.4%) | 0.303 | 3 (7.0%) | 2 (20.0%) | 0.486 |
| Time from illness onset to first hospital admission | 7.0 (6.0–9.2) | 7.0 (4.5–9.0) | 7.0 (7.0–9.0) | 0.268 | 7.0 (7.0–9.0) | 6.7 (2.9) | 0.588 |
| Signs and symptoms | |||||||
| High fever | 91 (78.4%) | 51 (81.0%) | 40 (75.5%) | 0.475 | 31 (72.1%) | 9 (90.0%) | 0.236 |
| Fever | 112 (96.6%) | 61 (96.8%) | 51 (96.2%) | 0.860 | 41 (95.3%) | 10 (100.0%) | 0.487 |
| Cough | 76 (65.5%) | 42 (66.7%) | 34 (64.2%) | 0.776 | 26 (60.5%) | 8 (80.0%) | 0.246 |
| Dyspnea | 54 (46.6%) | 26 (41.3%) | 28 (52.8%) | 0.214 | 22 (51.2%) | 6 (60.0%) | 0.614 |
| Muscle ache | 14 (12.1%) | 10 (15.9%) | 4 (7.5%) | 0.170 | 4 (9.3%) | 0 (0%) | 0.316 |
| Headache | 27 (23.3%) | 18 (28.6%) | 9 (17.0%) | 0.141 | 8 (18.6%) | 1 (10.0%) | 0.514 |
| Dizzyness | 27 (23.3%) | 13 (20.6%) | 14 (26.4%) | 0.463 | 10 (23.3%) | 4 (40.0%) | 0.279 |
| Stomach ache | 3 (2.6%) | 1 (1.6%) | 2 (3.8%) | 0.460 | 2 (4.7%) | 0 (0%) | 0.487 |
| Diarrhea | 6 (5.2%) | 4 (6.3%) | 2 (3.8%) | 0.533 | 1 (2.3%) | 1 (10.0%) | 0.251 |
| Fatigue | 52 (44.8%) | 29 (46.0%) | 23 (43.4%) | 0.776 | 16 (37.2%) | 7 (70.0%) | 0.059 |
| Vomit | 14 (12.1%) | 8 (12.7%) | 6 (11.3%) | 0.821 | 4 (9.3%) | 2 (20.0%) | 0.336 |
| Runny nose | 3 (2.6%) | 1 (1.6%) | 2 (3.8%) | 0.460 | 2 (4.7%) | 0 (0%) | 0.487 |
| Severity of illness scores | |||||||
| APACHE II | 11.0 (9.0–13.2) | 9.4 (3.8) | 13.0 (11.0–18.0) | < 0.001 | 11.0 (11.0–16.5) | 19.4 (6.9) | 0.028 |
| SOFA | 2.0 (1.0–3.0) | 2.0 (0.5–2.0) | 3.0 (2.0–6.0) | < 0.001 | 3.0 (2.0–6.0) | 5.4 (2.2) | 0.041 |
| PSI | 2.9 (1.1) | 3.0 (1.5–3.0) | 3.0 (3.0–4.0) | < 0.001 | 3.4 (0.8) | 4.2 (0.9) | 0.013 |
APACHE II Acute Physiology and Chronic Health Evaluation II, SOFA Sequential Organ Failure Assessment, PSI Pneumonia Severity Index